Oxybutynin | AChR | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / 神经信号通路 / AChR / Oxybutynin

奥昔布宁 /Oxybutynin 98%

货号：A144038

Oxybutynin a synthetic anticholinergic agent used for treatment of urinary incontinence and overactive bladder syndrome, with elimination half-life of ‎12.4–13.2 hours.

Oxybutynin 化学结构
CAS号：5633-20-5

Oxybutynin 3D分子结构
CAS号：5633-20-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Oxybutynin 纯度/质量文件产品仅供科研

货号：A144038 标准纯度： 98% 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell,2024. Ambeed. [ A125712 ]; • Cancer Discov., 2024. Ambeed. [ A285925 ]; • JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]; • JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]; • EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]; 更多 >

AChR 亚型比较

产品名称	AChE ↓ ↑	AChR ↓ ↑	mAChR ↓ ↑	nAChR ↓ ↑	其他靶点	纯度
Donepezil	+++ bAChE, IC50: 8.12 nM hAChE, IC50: 11.6 nM					98%
Loganin	++ AChE, IC50: 3.95 μM					99%+
topride HCl	++ AChE, IC50: 2.04 μM					98%
Dehydroevodiamine HCl	✔					99%+
Jatrorrhizine	++ AChE, IC50: 872 nM					99%+
Palmatine	++ AChE, IC50: 0.51 μM					98%
(-)-Huperzine A	++++ AChE (G4 form), Ki: 7 nM					98%
Galanthamine HBr	++ AChE, IC50: 0.35 μM					98%
Trospium chloride		✔				99%
Tiotropium Bromide Monohydrate		✔				98+%
Gallamine Triethiodide		+ AChR, IC50: 68.0 μM				98%
Hexamethonium Bromide		✔				99%
Pancuronium dibromide		✔				98%
Neostigmine bromide		✔				98%
Orphenadrine citrate		✔				98%
Oxybutynin		✔				98%
Irsogladine		✔			PDE	98%
Pyridostigmine bromide		✔				99+%
Rivastigmine		+ AChR, IC50: 5.5 μM				98%
Paroxetine hydrochloride		✔				97%
Rocuronium Bromide		✔				98%
Tropicamide			+++ M4 mAChR, IC50: 8 nM			98%
Diphenmanil methylsulfate			✔			98%
Umeclidinium bromide			✔			95%
Otilonium bromide			✔			98%
Flavoxate HCl			+ mAChR, IC50: 12.2 μM			98%
Ipratropium bromide			✔			98%
Diphenidol HCl			✔			98%
Darifenacin hydrobromide			++++ M3 mAChR, pKi: 8.9			98%
Aclidinium Bromide			++++ M4 mAChR, Ki: 0.21 nM M2 mAChR, Ki: 0.1 nM			98%
Oxybutynin chloride			✔			99%
Pentoxyverine citrate			✔			98%
Solifenacin			✔			98%
Catharanthine				✔		98%
Benzethonium chloride				+++ α7 nAChRs, IC50: 122 nM α4β2 nAChRs, IC50: 49 nM		99+%
Vinblastine sulfate				+ nAChR, IC50: 8.9 μM		99%
PNU-120596				++ α7 nAChR, EC50: 216 nM		99+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Oxybutynin 生物活性

靶点

AChR

描述

Oxybutynin (OXY) is a competitive acetylcholine antagonist that relaxes the bladder smooth muscle. In patients with involuntary detrusor contractions, OXY increases bladder capacity and volume to first detrusor contraction, thus decreasing urinary urgency and frequency of urination^[3]. Moreover, Oxybutynin inhibited vascular Kv channels in a concentration-dependent manner, with an IC₅₀ value of 11.51 ± 0.38 μM and a Hill coefficient (n) of 2.25 ± 0.12^[4].

Oxybutynin 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02809274	-		Unknown	August 2018	Israel ... 展开 >> Emek Medical center Not yet recruiting Afula, Israel Contact: Evgeni Chubar, Dr Soroka medical center Not yet recruiting Beer Sheva, Israel Contact: Anna Gurevich Hillel Yaffe Medical Center Not yet recruiting Hadera, Israel Contact: Lea Arbov Bnei Zion medical center Not yet recruiting Haifa, Israel Contact: Yelena Mischenko, Dr Rambam Medical center Not yet recruiting Haifa, Israel Contact: Noa Lavi Meir Medical center Not yet recruiting Kfar Saba, Israel Contact: Martin Ellis, Prof Principal Investigator: Martin Ellis Sheba medical center Not yet recruiting Ramat Gan, Israel Contact: Adrian Duek Kaplan medical center Not yet recruiting Rehovot, Israel Contact: Anfisa Santevsky, Dr Maccabi Not yet recruiting Tel Aviv, Israel Contact: Sigal Tavor, Dr Sub-Investigator: Shirly Shapira, Dr Tel Aviv Sourasky Not yet recruiting Tel Aviv, Israel Contact: Irit Avivi, Prof Ziv Medical center Not yet recruiting Zefat, Israel Contact: Nagib Dali Assaf Harofeh Medical Center Not yet recruiting Zerifin, Israel Contact: Odit Gotvin, Dr 收起 <<
NCT02386072	-		Completed	-	-
NCT00547378	Urinary Incontinence, Urgency-... 展开 >>frequency Overactive Bladder 收起 <<	Phase 4	Completed	-	-

Oxybutynin 参考文献

[1]Lukkari E, Taavitsainen P, et al. Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. Pharmacol Toxicol. 1998 Apr;82(4):161-6.

[2]Tonini M, Rizzi CA, et al. Depressant action of oxybutynin on the contractility of intestinal and urinary tract smooth muscle. J Pharm Pharmacol. 1987 Feb;39(2):103-7.

[3]Davila GW. Transdermal oxybutynin in the treatment of overactive bladder. Clin Interv Aging. 2006;1(2):99-105. doi: 10.2147/ciia.2006.1.2.99. PMID: 18044106; PMCID: PMC2695169.

[4]Li H, Seo MS, An JR, Jung HS, Ha KS, Han ET, Hong SH, Bae YM, Ryu DR, Park WS. The anticholinergic drug oxybutynin inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells. Clin Exp Pharmacol Physiol. 2019 Nov;46(11):1030-1036. doi: 10.1111/1440-1681.13138. Epub 2019 Aug 9. PMID: 31330060.

Oxybutynin 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.80mL

0.56mL

0.28mL

13.99mL

2.80mL

1.40mL

27.97mL

5.59mL

2.80mL

Oxybutynin 技术信息

CAS号	5633-20-5
分子式	C₂₂H₃₁NO₃
分子量	357.486

别名
运输	蓝冰

存储条件

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 105 mg/mL(293.72 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 50 mg/mL(139.87 mM)

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02809274	-		Unknown	August 2018	Israel ... 展开 >> Emek Medical center Not yet recruiting Afula, Israel Contact: Evgeni Chubar, Dr Soroka medical center Not yet recruiting Beer Sheva, Israel Contact: Anna Gurevich Hillel Yaffe Medical Center Not yet recruiting Hadera, Israel Contact: Lea Arbov Bnei Zion medical center Not yet recruiting Haifa, Israel Contact: Yelena Mischenko, Dr Rambam Medical center Not yet recruiting Haifa, Israel Contact: Noa Lavi Meir Medical center Not yet recruiting Kfar Saba, Israel Contact: Martin Ellis, Prof Principal Investigator: Martin Ellis Sheba medical center Not yet recruiting Ramat Gan, Israel Contact: Adrian Duek Kaplan medical center Not yet recruiting Rehovot, Israel Contact: Anfisa Santevsky, Dr Maccabi Not yet recruiting Tel Aviv, Israel Contact: Sigal Tavor, Dr Sub-Investigator: Shirly Shapira, Dr Tel Aviv Sourasky Not yet recruiting Tel Aviv, Israel Contact: Irit Avivi, Prof Ziv Medical center Not yet recruiting Zefat, Israel Contact: Nagib Dali Assaf Harofeh Medical Center Not yet recruiting Zerifin, Israel Contact: Odit Gotvin, Dr 收起 <<
NCT02386072	-		Completed	-	-
NCT00547378	Urinary Incontinence, Urgency-... 展开 >>frequency Overactive Bladder 收起 <<	Phase 4	Completed	-	-
NCT03572231	-		Recruiting	December 2019	Korea, Republic of ... 展开 >> Site KR410008 Recruiting Daejeon, Korea, Republic of Site KR410009 Recruiting Incheon, Korea, Republic of Site KR410001 Recruiting Seoul, Korea, Republic of Site KR410003 Recruiting Seoul, Korea, Republic of Site KR410006 Recruiting Seoul, Korea, Republic of Taiwan Site TW158001 Recruiting Hualien City, Taiwan 收起 <<
NCT02865395	Overactive Bladder	Phase 4	Terminated(Another study publi... 展开 >>shed with similar results) 收起 <<	-	United States, District of Col... 展开 >>umbia George Washington University Washington, District of Columbia, United States, 20037 收起 <<
NCT00175123	Myelomeningocele ... 展开 >> Bladder, Neurogenic 收起 <<	Phase 4	Unknown	June 2008	Denmark ... 展开 >> Department of Urology, Aarhus University Hospital, Section Skejby Aarhus, Aarhus N, Denmark, 8200 收起 <<
NCT01829425	Urinary Incontinence, Urge	Not Applicable	Completed	-	United States, New Mexico ... 展开 >> University of New Mexico Health Science Center Albuquerque, New Mexico, United States, 87131 收起 <<
NCT03602508	-		Active, not recruiting	February 2019	Australia ... 展开 >> Site AU10000 Sydney, Australia Korea, Republic of Site KR82001 Seoul, Korea, Republic of 收起 <<
NCT00366002	Overactive Bladder (OAB)	Phase 4	Completed	-	-
NCT00547378	-		Completed	-	-
NCT00892450	Parkinson's Disease ... 展开 >> Overactive Bladder 收起 <<	Not Applicable	Completed	-	United States, Pennsylvania ... 展开 >> VA Medical Center, Philadelphia Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT01148186	Polypharmacy ... 展开 >>Incontinence Insomnia Anxiety 收起 <<	Phase 4	Terminated(Study funding perio... 展开 >>d reached conclusion. Sample size sufficient to complete the analysis on benzodiazepines.) 收起 <<	-	Canada, Quebec ... 展开 >> Le Groupe Jean Coutu Inc. Longueuil, Quebec, Canada, J4G 1S8 收起 <<
NCT00800462	Spinal Cord Injury ... 展开 >> Neurogenic Detrusor Overactivity 收起 <<	Phase 4	Completed	-	Canada, Manitoba ... 展开 >> University of Manitoba, Health Sciences Centre Winnipeg, Manitoba, Canada, R3A1R9 Canada, Ontario Toronto Rehabilitation Institute, Lyndhurst Centre Toronto, Ontario, Canada, M4G 3V9 收起 <<
NCT01557244	Urinary Bladder, Neurogenic	Phase 3	Recruiting	November 13, 2019	-
NCT01450332	Anterior Cruciate Ligament Rup... 展开 >>ture 收起 <<	Not Applicable	Unknown	January 2013	Israel ... 展开 >> Shhare Zedek Medical Center Recruiting Jerusalem, Israel, 91031 Principal Investigator: Yoram Litwin, MD 收起 <<
NCT01187498	-		Completed	-	-
NCT00629642	Multiple Sclerosis ... 展开 >> Neurogenic Bladder Spinal Cord Diseases 收起 <<	Phase 4	Completed	-	-
NCT01187498	Overactive Bladder	Phase 3	Completed	-	United States, Alabama ... 展开 >> Birmingham VA Medical Center Birmingham, Alabama, United States, 35233 United States, Georgia Atlanta VA Medical and Rehab Center, Decatur Decatur, Georgia, United States, 30033 收起 <<
NCT01824420	Overactive Bladder	Phase 4	Completed	-	Taiwan ... 展开 >> Buddhist Tzu Chi General Hospital Hualien, Taiwan, 970 收起 <<
NCT01899794	Urinary Incontinence Mixed (St... 展开 >>ress and Urge) 收起 <<	Phase 4	Completed	-	-
NCT00411437	Memory Cognit... 展开 >>ion 收起 <<	Phase 4	Completed	-	United States, Arizona ... 展开 >> Pfizer Investigational Site Tucson, Arizona, United States, 85741 United States, Florida Pfizer Investigational Site Brooksville, Florida, United States, 34613 Pfizer Investigational Site DeLand, Florida, United States, 32720 Pfizer Investigational Site Naples, Florida, United States, 34102 Pfizer Investigational Site Ocala, Florida, United States, 34471 Pfizer Investigational Site Ocala, Florida, United States, 34474 Pfizer Investigational Site St. Petersburg, Florida, United States, 33709 Pfizer Investigational Site Tampa, Florida, United States, 33606 Pfizer Investigational Site West Palm Beach, Florida, United States, 33407 收起 <<
NCT01370811	Sialorrhoea	Phase 2	Completed	-	United States, Michigan ... 展开 >> QUEST Research Institute Bingham Farms, Michigan, United States, 48025 收起 <<
NCT02704013	Overactive Bladder	Not Applicable	Unknown	December 2017	Croatia ... 展开 >> Children's Hospital Zagreb Zagreb, Croatia, 10000 收起 <<
NCT00223821	Urinary Incontinence	Not Applicable	Completed	-	United States, Alabama ... 展开 >> Birmingham VA Medical Center Birmingham, Alabama, United States, 35233 收起 <<
NCT01126424	-		Completed	-	-
NCT00501267	Overactive Bladder	Phase 1	Completed	-	United States, Washington ... 展开 >> GSK Investigational Site Tacoma, Washington, United States, 98418 收起 <<
NCT00223821	-		Completed	-	-
NCT01178827	-		Completed	-	-
NCT01178827	Overactive Bladder	Phase 4	Completed	-	United States, Utah ... 展开 >> Salt Lake City, Utah, United States 收起 <<
NCT03050827	Diabetic; Neuropathic, Polyneu... 展开 >>ropathy (Manifestation) 收起 <<	Phase 3	Completed	-	United States, Virginia ... 展开 >> Eastern Virgnia Medical School, Strelitz Diabetes Center Norfolk, Virginia, United States, 23510f 收起 <<
NCT02070042	Overactive Bladder	Not Applicable	Terminated(Lack of participati... 展开 >>on) 收起 <<	-	United States, Ohio ... 展开 >> Good Samaritan Hospital Cincinnati, Ohio, United States, 45220 收起 <<
NCT02176642	-		Terminated	-	-
NCT00269750	Urge Incontinence	Phase 3	Completed	-	-
NCT02176642	Urinary Urge Incontinence	Phase 4	Terminated	-	United States, North Carolina ... 展开 >> Duke Urogynecology Durham, North Carolina, United States, 27707 Duke OB/GYN Consultants of Raleigh Raleigh, North Carolina, United States, 27607 收起 <<
NCT00304499	Urinary Incontinence	Phase 3	Completed	-	-
NCT00224146	Overactive Bladder ... 展开 >> Urinary Incontinence Quality of Life 收起 <<	Phase 4	Completed	-	United States, Alabama ... 展开 >> Mobile, Alabama, United States United States, Arizona Tucson, Arizona, United States United States, California Torrance, California, United States United States, Connecticut Rocky Hill, Connecticut, United States United States, Georgia Valdosta, Georgia, United States United States, Louisiana Gretna, Louisiana, United States United States, Michigan Bloomfield Hills, Michigan, United States United States, New York Poughkeepsie, New York, United States United States, North Carolina Winston-Salem, North Carolina, United States United States, Texas Tomball, Texas, United States 收起 <<
NCT00338624	Urination Disorders	Phase 3	Completed	-	-
NCT00990886	Menopause Hot... 展开 >> Flashes 收起 <<	Phase 2	Completed	-	-
NCT01126424	Cognition	Phase 4	Completed	-	United Kingdom ... 展开 >> Blackpool, Lancashire, United Kingdom, FY2 0JH Manchester, Lancashire, United Kingdom, M50 2GY Bradford, Yorkshire, United Kingdom, BD3 0DQ 收起 <<
NCT00649272	Healthy	Phase 1	Completed	-	United States, North Dakota ... 展开 >> PRACS Institute Ltd. - Cetero Research Fargo, North Dakota, United States, 58104 收起 <<
NCT00650481	Healthy	Phase 1	Completed	-	United States, North Dakota ... 展开 >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 收起 <<
NCT00293839	Urinary Incontinence	Phase 3	Completed	-	-
NCT00648843	Healthy	Phase 1	Completed	-	United States, North Dakota ... 展开 >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 收起 <<
NCT00350636	Overactive Bladder	Phase 3	Completed	-	-
NCT00749632	Urinary Incontinence, Urge	Phase 2	Completed	-	United States, Maryland ... 展开 >> SNBL Clinical Pharmacology Center Baltimore, Maryland, United States, 21201 United States, New Jersey Advanced Biomedical Research Hackensack, New Jersey, United States, 07601 收起 <<
NCT00350636	-		Completed	-	-
NCT00649259	Healthy	Phase 1	Completed	-	United States, West Virginia ... 展开 >> Kendle International Inc. Morgantown, West Virginia, United States, 26505 收起 <<
NCT00649727	Healthy	Phase 1	Completed	-	United States, West Virginia ... 展开 >> Kendle International Inc. Morgantown, West Virginia, United States, 26505 收起 <<
NCT00649129	Healthy	Phase 1	Completed	-	United States, West Virginia ... 展开 >> Kendle International Inc. Morgantown, West Virginia, United States, 26505 收起 <<
NCT00752141	Healthy Volunteers	Phase 1	Completed	-	United States, Arizona ... 展开 >> Tucson, Arizona, United States, 85741-3656 United States, California National City, California, United States, 91950 United States, Florida Maitland, Florida, United States, 32751 Naples, Florida, United States, 34102 Ocala, Florida, United States, 34471 United States, Georgia Atlanta, Georgia, United States, 30341-4155 收起 <<
NCT01716624	Neurogenic Bladder	Phase 3	Completed	-	Canada, Ontario ... 展开 >> London Health Sciences Centre - Victoria Hospital London, Ontario, Canada, N6A 5W9 收起 <<
NCT00926926	Healthy	Phase 1	Completed	-	United States, Missouri ... 展开 >> St. Charles, Missouri, United States 收起 <<
NCT00269724	Urinary Incontinence	Phase 3	Completed	-	-
NCT02240459	Overactive Bladder ... 展开 >> Mild Cognitive Impairment 收起 <<	Phase 2	Recruiting	December 2019	Canada, Alberta ... 展开 >> Division of Geriatric Medicine, Clinical Sciences Building, University of Alberta Hosp Recruiting Edmonton, Alberta, Canada, T6G 2P4 Contact: Adrian Wagg, MD 780 492 5338 adrian.wagg@ualberta.ca Contact: Saima Rajabali, MBBS 780 492 3700 srajabal@ualberta.ca Principal Investigator: Adrian S Wagg, MD Sub-Investigator: Saima Rajabali, MBBS Sub-Investigator: William Gibson, MBBS 收起 <<
NCT00816972	Post-nasal Drip ... 展开 >> Seasonal Allergic Rhinitis Rhinorrhea 收起 <<	Phase 2	Completed	-	-
NCT00170768	Healthy Volunteers	Phase 2	Completed	-	United States, District of Col... 展开 >>umbia Washington Neuropsychological Institute LLC Georgetown Washington, District of Columbia, United States, 20016 收起 <<
NCT00431041	-		Completed	-	-
NCT02522936	Overactive Bladder ... 展开 >> Xerostomia Compliance 收起 <<	Phase 4	Withdrawn(Due to lack of fundi... 展开 >>ng and necessary personnel we determined that the study could not be done.) 收起 <<	December 30, 2019	-
NCT00431041	Overactive Bladder	Phase 4	Completed	-	Canada, Alberta ... 展开 >> Calgary, Alberta, Canada, T2V 4R6 Edmonton, Alberta, Canada, T5H 3V9 Canada, British Columbia Vancouver, British Columbia, Canada, V6T 2B5 Victoria, British Columbia, Canada, V8T 5G1 Canada, Nova Scotia Halifax, Nova Scotia, Canada, B3H 3A7 Canada, Ontario Guelph, Ontario, Canada, N1H 5J1 Kitchener, Ontario, Canada, N2N 2B9 Toronto, Ontario, Canada, M4N 3M5 Toronto, Ontario, Canada, M5G 1Z5 Toronto, Ontario, Canada, M5T 2S8 Toronto, Ontario, Canada, M6A 3B5 Canada, Quebec Montreal, Quebec, Canada, H3T 1E2 收起 <<
NCT00224016	-		Completed	-	-
NCT00224029	Detrusor Hyperreflexia	Phase 4	Completed	-	United States, Georgia ... 展开 >> Atlanta, Georgia, United States United States, New York Bronx, New York, United States United States, North Carolina Chapel Hill, North Carolina, United States Charlotte, North Carolina, United States United States, Texas Dallas, Texas, United States Houston, Texas, United States 收起 <<
NCT01956591	-		Completed	-	Brazil ... 展开 >> Hospital Israelita Albert Einstein São Paulo, Brazil, 05652000 收起 <<
NCT02961790	Breast Carcinoma ... 展开 >> Ductal Breast Carcinoma In Situ Hot Flashes Lobular Breast Carcinoma In Situ No Evidence of Disease 收起 <<	Phase 3	Active, not recruiting	May 1, 2019	United States, Illinois ... 展开 >> Illinois CancerCare-Peoria Peoria, Illinois, United States, 61615 Carle Cancer Center NCI Community Oncology Research Program Urbana, Illinois, United States, 61801 United States, Iowa Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa, United States, 52403 United States, Kansas Cancer Center of Kansas - Wichita Wichita, Kansas, United States, 67214 United States, Kentucky Saint Elizabeth Medical Center South Edgewood, Kentucky, United States, 41017 United States, Michigan Michigan Cancer Research Consortium NCORP Ann Arbor, Michigan, United States, 48106 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, North Carolina Waverly Hematology Oncology Cary, North Carolina, United States, 27518 United States, South Carolina AnMed Health Cancer Center Anderson, South Carolina, United States, 29621 United States, South Dakota Rapid City Regional Hospital Rapid City, South Dakota, United States, 57701 United States, Wisconsin Saint Vincent Hospital -Green Bay Green Bay, Wisconsin, United States, 54301 University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Marshfield Clinic Marshfield, Wisconsin, United States, 54449 收起 <<
NCT02483793	Disorder of Urinary Stent	Not Applicable	Unknown	December 2016	-
NCT00224029	-		Completed	-	-
NCT03205605	Heat Effect	Early Phase 1	Recruiting	February 28, 2019	United States, Maryland ... 展开 >> General Clinical Research Center (GCRC) at the University of Maryland Medical Center Recruiting Baltimore, Maryland, United States, 21201 收起 <<
NCT01796548	Detrusor Function, Overactive	Phase 4	Terminated(Slow rate of partic... 展开 >>ipant's enrollment) 收起 <<	-	Thailand ... 展开 >> Bangkok, Thailand Chiangmai, Thailand Phathumwan, Thailand 收起 <<
NCT00613327	Urinary Bladder, Overactive	Phase 4	Completed	-	-
NCT00224016	Detrusor Hyperreflexia	Phase 4	Completed	-	-
NCT00613327	-		Completed	-	-
NCT01423838	Overactive Bladder	Phase 4	Unknown	September 2012	Turkey ... 展开 >> Turkish Republic Ministry of Health Adana Numune Training and Research Hospital Not yet recruiting Adana, Turkey, 01150 Contact: Murat Api, M.D., Ph.D. +905424241807 muratapi@hotmail.com Contact: Hakan Aytan, M.D. +905056833866 drhakanaytan@yahoo.com 收起 <<
NCT02973659	Hyperhidrosis	Not Applicable	Completed	-	-
NCT00909181	Urge Urinary Incontinence ... 展开 >> Urinary Frequency 收起 <<	Phase 3	Completed	-	-
NCT01477736	Spinal Cord Injury	Not Applicable	Completed	-	Brazil ... 展开 >> UNICAMP, Division of Urology Campinas, Sao Paulo, Brazil, 13083887 收起 <<
NCT01050114	Overactive Bladder	Phase 3	Unknown	July 2018	United States, Texas ... 展开 >> Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Sebrina Tello 713-798-8106 stello@bcm.edu TIRR-Memorial Hermann Not yet recruiting Houston, Texas, United States, 77030 Contact: Sebrina Tello 713-798-8106 stello@bcm.edu Sub-Investigator: John E. Bertini, Jr., MD 收起 <<
NCT00909181	-		Completed	-	-
NCT01118429	Axillary Hyperhidrosis ... 展开 >> Osmidrosis 收起 <<	Not Applicable	Completed	-	Brazil ... 展开 >> Hospital das Clinicas da FMUSP Sao Paulo, Brazil, 04534000 收起 <<
NCT02327936	Overactive Bladder	Phase 3	Completed	-	-
NCT01328015	Hyperhidrosis	Phase 2	Completed	-	-
NCT01192568	Overactive Detrusor ... 展开 >> Neurogenic Bladder 收起 <<	Phase 4	Recruiting	June 12, 2020	United States, California ... 展开 >> Loma Linda University Health Recruiting Loma Linda, California, United States, 92354 Atlantic Urology Medical Group Terminated Long Beach, California, United States, 90806 Cedars-Sinai Medical Center Recruiting Los Angeles, California, United States, 90048 Children's Hospital of Orange County Recruiting Orange, California, United States, 92868 United States, Colorado Urology Associates Recruiting Englewood, Colorado, United States, 80113 United States, Georgia Augusta University Recruiting Augusta, Georgia, United States, 30912 United States, Michigan Children's Hospital of Michigan Terminated Detroit, Michigan, United States, 48201 United States, Mississippi University of Mississippi Medical Center Recruiting Jackson, Mississippi, United States, 39216 United States, New York Albany Medical College Not yet recruiting Albany, New York, United States, 12208 United States, North Carolina Carolinas Medical Center Recruiting Charlotte, North Carolina, United States, 28207 Associated Urologists of North Carolina Recruiting Raleigh, North Carolina, United States, 27612 United States, Ohio Children's Hospital Medical Center of Akron Terminated Akron, Ohio, United States, 44308 United States, Oregon Oregon Health and Science University Not yet recruiting Portland, Oregon, United States, 97239 United States, Texas Texas Children's Hospital - BCM Not yet recruiting Houston, Texas, United States, 77030 United States, Virginia Children's Hospital of the King's Daughters Recruiting Norfolk, Virginia, United States, 23507 Puerto Rico Centro de Investigaciones Clinicas, San Jorge Children's Hospital Recruiting San Juan, Puerto Rico, 00912 收起 <<
NCT02908529	Obstructive Sleep Apnea (OSA)	Phase 1 Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Sleep Disorders Research Program Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 收起 <<
NCT02633371	Hyperhidrosis	Not Applicable	Completed	-	United States, Colorado ... 展开 >> Children's Hospital, Colorado Aurora, Colorado, United States, 80045 收起 <<
NCT02099695	Hyperhidrosis	Phase 3	Withdrawn(The company changed ... 展开 >>the strategy.) 收起 <<	February 2016	Brazil ... 展开 >> Hospital Israelita Albert Einstein São Paulo, Brazil, 05652-90 Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo São Paulo, Brazil 收起 <<
NCT01855256	Hyperhidrosis	Phase 3	Completed	-	France ... 展开 >> Hospital, Brest Brest, France, 29609 CHG Landerneau Landerneau, France, 29800 CHG de Morlaix Morlaix, France, 29600 Dermatologist'S Office Quimper, France, 29000 收起 <<
NCT02538302	Nocturnal Enuresis	Phase 3	Completed	-	Iran, Islamic Republic of ... 展开 >> Shahid Mohammadi hospital Bandar Abbas, Hormozgan, Iran, Islamic Republic of, 79176 收起 <<
NCT01310712	Hyperhidrosis	Phase 4	Completed	-	Brazil ... 展开 >> Hospital das Clinicas da FMUSP Sao Paulo, Brazil, 05679040 收起 <<
NCT02633371	-		Completed	-	-
NCT03187795	Spinal Cord Injuries ... 展开 >> Urinary Bladder, Neurogenic 收起 <<	Phase 2	Not yet recruiting	March 30, 2022	United States, New Jersey ... 展开 >> Kessler Institute for Rehabilitation Not yet recruiting West Orange, New Jersey, United States, 07052 Contact: Todd A. Linsenmeyer, M.D. 973-243-6924 tlinsenmeyer@kessler-rehab.com Contact: Trevor A. Dyson-Hudson, M.D. 973-324-3576 tdysonhudson@kesslerfoundation.org Principal Investigator: Todd A. Linsenmeyer, M.D. Principal Investigator: Steven C. Kirshblum, M.D. Principal Investigator: Trevor A. Dyson-Hudson, M.D. 收起 <<
NCT01796548	-		Terminated(Slow rate of partic... 展开 >>ipant's enrollment) 收起 <<	-	-

奥昔布宁 /Oxybutynin 98%

Oxybutynin 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Oxybutynin 质控信息

Oxybutynin 生物活性

Oxybutynin 临床研究

Oxybutynin 参考文献

Oxybutynin 实验方案

Oxybutynin 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

奥昔布宁 /Oxybutynin 98%

Oxybutynin 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Oxybutynin 质控信息

Oxybutynin 生物活性

Oxybutynin 临床研究

Oxybutynin 参考文献

Oxybutynin 实验方案

Oxybutynin 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Oxybutynin 纯度/质量文件产品仅供科研